LS Investment Advisors LLC reduced its position in Eli Lilly And Co (NYSE:LLY) by 13.4% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 23,837 shares of the company’s stock after selling 3,699 shares during the period. LS Investment Advisors LLC’s holdings in Eli Lilly And Co were worth $2,758,000 at the end of the most recent quarter.
Other institutional investors have also recently bought and sold shares of the company. Ironwood Financial llc purchased a new position in shares of Eli Lilly And Co during the 4th quarter worth approximately $30,000. Csenge Advisory Group purchased a new position in shares of Eli Lilly And Co during the 3rd quarter worth approximately $58,000. Atwood & Palmer Inc. raised its stake in shares of Eli Lilly And Co by 267.0% during the 4th quarter. Atwood & Palmer Inc. now owns 734 shares of the company’s stock worth $85,000 after buying an additional 534 shares in the last quarter. Cornerstone Advisors Inc. raised its stake in shares of Eli Lilly And Co by 21.3% during the 3rd quarter. Cornerstone Advisors Inc. now owns 776 shares of the company’s stock worth $83,000 after buying an additional 136 shares in the last quarter. Finally, First Command Bank raised its stake in shares of Eli Lilly And Co by 31.3% during the 4th quarter. First Command Bank now owns 834 shares of the company’s stock worth $96,000 after buying an additional 199 shares in the last quarter. 80.84% of the stock is owned by institutional investors and hedge funds.
In other news, SVP Alfonso G. Zulueta sold 4,000 shares of the firm’s stock in a transaction on Thursday, January 31st. The stock was sold at an average price of $120.00, for a total transaction of $480,000.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, major shareholder Lilly Endowment Inc sold 200,000 shares of the firm’s stock in a transaction on Friday, November 16th. The stock was sold at an average price of $113.74, for a total value of $22,748,000.00. Following the sale, the insider now owns 118,600,804 shares in the company, valued at approximately $13,489,655,446.96. The disclosure for this sale can be found here. In the last quarter, insiders have sold 817,843 shares of company stock worth $94,595,335. 0.11% of the stock is owned by insiders.
Eli Lilly And Co (NYSE:LLY) last announced its earnings results on Wednesday, February 6th. The company reported $1.33 EPS for the quarter, missing analysts’ consensus estimates of $1.36 by ($0.03). The company had revenue of $6.44 billion for the quarter, compared to analyst estimates of $6.28 billion. Eli Lilly And Co had a net margin of 13.16% and a return on equity of 42.55%. Eli Lilly And Co’s quarterly revenue was up 4.5% compared to the same quarter last year. During the same quarter last year, the company posted $1.14 EPS. As a group, equities research analysts forecast that Eli Lilly And Co will post 5.6 earnings per share for the current year.
The business also recently announced a quarterly dividend, which will be paid on Friday, March 8th. Shareholders of record on Friday, February 15th will be issued a dividend of $0.645 per share. This represents a $2.58 dividend on an annualized basis and a yield of 2.19%. The ex-dividend date of this dividend is Thursday, February 14th. This is a boost from Eli Lilly And Co’s previous quarterly dividend of $0.56. Eli Lilly And Co’s dividend payout ratio is 40.54%.
A number of equities analysts have recently issued reports on LLY shares. Zacks Investment Research raised Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $133.00 target price for the company in a research note on Wednesday, December 5th. UBS Group cut their target price on Eli Lilly And Co from $107.53 to $100.00 and set an “average” rating for the company in a research note on Friday. Cantor Fitzgerald reissued a “buy” rating and set a $128.00 target price on shares of Eli Lilly And Co in a research note on Wednesday, October 17th. Wolfe Research started coverage on Eli Lilly And Co in a research note on Tuesday, October 23rd. They set a “market perform” rating and a $119.00 target price for the company. Finally, Societe Generale set a $106.00 target price on Eli Lilly And Co and gave the stock a “hold” rating in a research note on Wednesday, November 7th. Eleven investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average price target of $111.41.
COPYRIGHT VIOLATION WARNING: “LS Investment Advisors LLC Trims Stake in Eli Lilly And Co (LLY)” was originally reported by Ticker Report and is owned by of Ticker Report. If you are accessing this story on another domain, it was copied illegally and republished in violation of international trademark and copyright legislation. The legal version of this story can be viewed at https://www.tickerreport.com/banking-finance/4146306/ls-investment-advisors-llc-trims-stake-in-eli-lilly-and-co-lly.html.
About Eli Lilly And Co
Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.
Further Reading: Is the QQQ ETF safe?
Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.